Literature DB >> 2413818

Clonidine in morphine withdrawal. Differential effects on signs and symptoms.

D R Jasinski, R E Johnson, T R Kocher.   

Abstract

Reports of an antiwithdrawal effect for clonidine hydrochloride in acute opioid withdrawal are inconsonant with experimental findings that other nonopioids are ineffective. In the present investigation the antiwithdrawal effects of clonidine, morphine sulfate, and placebo were compared in volunteer addicts whose dependence was maintained by 15 mg of morphine sulfate given subcutaneously four times daily. Clonidine was effective but had a differential effect on the signs and symptoms of morphine abstinence. Compared with morphine, clonidine was more effective in suppressing autonomic signs of abstinence but less effective in reducing subject-reported symptoms and discomfort. It is concluded that the perception of the clinical usefulness of clonidine depends on whether objective measures or subjects' reports are treated.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2413818     DOI: 10.1001/archpsyc.1985.01790340041006

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  33 in total

1.  Ambulatory opiate detoxification and primary care: a role for the primary care physician.

Authors:  P G O'Connor; M E Waugh; R S Schottenfeld; I A Diakogiannis; B J Rounsaville
Journal:  J Gen Intern Med       Date:  1992 Sep-Oct       Impact factor: 5.128

2.  Rapid neuroadaptation in the nucleus accumbens and bed nucleus of the stria terminalis mediates suppression of operant responding during withdrawal from acute opioid dependence.

Authors:  S H Criner; J Liu; G Schulteis
Journal:  Neuroscience       Date:  2006-12-11       Impact factor: 3.590

3.  Decreased brain reward produced by ethanol withdrawal.

Authors:  G Schulteis; A Markou; M Cole; G F Koob
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

4.  The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers.

Authors:  Ziva D Cooper; Kirk W Johnson; Martina Pavlicova; Andrew Glass; Suzanne K Vosburg; Maria A Sullivan; Jeanne M Manubay; Diana M Martinez; Jermaine D Jones; Phillip A Saccone; Sandra D Comer
Journal:  Addict Biol       Date:  2015-05-14       Impact factor: 4.280

5.  Interactions of clonidine and naloxone on schedule-controlled behavior in opioid-naive mice.

Authors:  J L Katz
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 6.  Is it prime time for alpha2-adrenocepter agonists in the treatment of withdrawal syndromes?

Authors:  Timothy E Albertson; James Chenoweth; Jonathan Ford; Kelly Owen; Mark E Sutter
Journal:  J Med Toxicol       Date:  2014-12

7.  Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.

Authors:  Jennifer R Schroeder; Karran A Phillips; David H Epstein; Michelle L Jobes; Melody A Furnari; Ashley P Kennedy; Markus Heilig; Kenzie L Preston
Journal:  Psychopharmacology (Berl)       Date:  2018-08-06       Impact factor: 4.530

8.  Primary care-based ambulatory opioid detoxification: the results of a clinical trial.

Authors:  P G O'Connor; M E Waugh; K M Carroll; B J Rounsaville; I A Diagkogiannis; R S Schottenfeld
Journal:  J Gen Intern Med       Date:  1995-05       Impact factor: 5.128

9.  Effects of prototypic calcium channel blockers in methadone-maintained humans responding under a naloxone discrimination procedure.

Authors:  Alison Oliveto; Michael Mancino; Nichole Sanders; Christopher Cargile; J Benjamin Guise; Warren Bickel; W Brooks Gentry
Journal:  Eur J Pharmacol       Date:  2013-03-21       Impact factor: 4.432

10.  Chronic infusion of clonidine does not alleviate spontaneous morphine withdrawal symptoms in rats.

Authors:  J W van der Laan; C Jansen van't Land
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.